Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Amgen

Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?

Results for Amgen's weight loss drug Maritide were highly anticipated, but fell short. However, MariTide could still turn the tables in future studies.

MarketBeat

Is Amgen Stock Underperforming the Dow?

Despite pharma giant Amgen trailing behind the Dow index over the past three months, analysts remain cautiously bullish about the stock's growth potential.

Barchart

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Stock Market Today: The S&P 500 Reclaims the 6K Level

Investors see Scott Bessent as a safe shepherd of the economy as the president-elect burnishes his "Tariff Man" reputation.

Kiplinger

Stocks Gain on Positive Corporate News and a Jump in US Consumer Confidence

The S&P 500 Index ($SPX ) (SPY ) today is up +0.25%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.59%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.45%. Stocks today are mixed, with some positive corporate news lifting the broader market. JM...

Barchart

Stocks Climb on Positive Corporate News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.25%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.40%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.48%. Stocks today are mixed, with some positive corporate news lifting the broader market. JM...

Barchart

Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau

Amgen's Phase 2 MariTide trial showed ~20% weight loss at 52 weeks, cardiometabolic improvements, and no significant safety issues.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

3 Top Healthcare Stocks to Buy for Growth and Dividends

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

Barchart

Is Amgen Stock Outperforming the Nasdaq?

Amgen has surpassed the Nasdaq recently, and analysts are cautiously optimistic about its future potential.

Barchart

AMGN Bullish Diagonal Trade Targets a Price of $350 by October 18th

A bullish diagonal spread is an advanced option trade and generally not suitable for beginners, but it can have its place within an option portfolio.

Barchart

Are Wall Street Analysts Bullish on Amgen Stock?

Amgen has outperformed the broader market over the past year, yet Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Barchart

What You Need to Know Ahead of Amgen's Earnings Release

Amgen is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.

Barchart

The Future of Weight-Loss Drugs for Investors

Weight-loss drugs’ impact could reach far beyond their target user, potentially creating headwinds for shares of snack makers and packaged-food firms, as well as medical device makers that specialize in knee replacements, insulin pumps and sleep apnea machines.

Kiplinger

Ark Invest CEO Cathie Wood Boosts Stake in Firms Making Breakthroughs in Gene Editing, AI Drug Development, and Obesity Drugs

Cathie Wood splurged millions in biotech this year on strong clinical progress, AI adoption, sales growth, wider outreach, and steady product pipelines.

International Business Times UK

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Biotech Stocks Poised for May Surges

The use of advanced technologies, growing demand for personalized medicines, and rising investments in R&D are boosting the biotech industry’s prospects. Given this backdrop, investors could consider buying quality biotech stocks: Amgen (AMGN), Jazz Pharmaceuticals (JAZZ), and ANI Pharmaceuticals (ANIP). Read on.

Barchart

Stocks Close Higher as the Outlook Improves for Fed Rate Cuts

The S&P 500 Index ($SPX ) (SPY ) Friday closed up +1.26%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.99%. US stock indexes Friday settled moderately higher, with the S&P 500 and Nasdaq 100...

Kiplinger

Stock Market Today: Stocks Soar on Apple Buyback News, Jobs Data

The main indexes rallied hard to end the week thanks to Apple's $110 billion stock repurchase plan and a big April payrolls miss.

Barchart

Stocks Climb as US Jobs Report Ramps Up Fed Rate Cut Expectations

The S&P 500 Index ($SPX ) (SPY ) this morning is +0.86%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.81%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.65%. US stock indexes this morning are moderately higher, with the S&P 500 and Nasdaq...

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Stocks Jump on Apple Earnings and Dovish Apr Payroll Report

The S&P 500 Index ($SPX ) (SPY ) this morning is +1.00%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.17%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.59%. US stock indexes this morning are moderately higher, with the S&P 500 and Nasdaq...

Barchart

Stocks Climb Before the Open After Fed Decision, Apple Earnings on Tap

June S&P 500 E-Mini futures (ESM24) are up +0.58%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.77% this morning after Federal Reserve Chair Jerome Powell appeared to rule out the possibility of further interest-rate hikes, while investors looked ahead to a new round of U.S. economic data and…

Barchart

3 Best Dividend ETFs to Buy for Passive Income

High-yield dividend ETFs, such as SCHD, offer investors the ability to create a passive income stream for life at a relatively low cost.

Fortune

The FTC should embrace proactive problem-solving

The legal precedent would strongly discourage companies from trying to solve perceived problems with proposed transactions.

Fortune

Competition cop Lina Khan’s antitrust overreach is hurting U.S. competitiveness–and destroying billions of dollars in value

Antitrust overreach is hurting America's global competitiveness, with the FTC calculating industry concentration on a purely domestic basis.

StockNews.com

November Buy Alert: 3 Biotech Stocks Making Gains

Given the breakthrough developments and the rising need to treat chronic diseases, the biotech industry is well-positioned to generate returns. This might make buying biotech stocks like Organogenesis Holdings (ORGO), Innoviva (INVA), and Amgen (AMGN) a wise decision this November. Read on….

StockNews.com

Amgen (AMGN) Earnings Watch: Buy or Sell?

Amgen (AMGN) is scheduled to report its third-quarter earnings soon, with Wall Street analysts expecting year-over-year improvements in revenue. However, its earnings are expected to miss the consensus estimate. Moreover, the company completed the acquisition of Horizon Therapeutics earlier this month. Considering these factors, is the stock a buy or…

1 … 3 4 5 6

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.